Ipilimumab
Metastatic Malignant Neoplasm In The Brain
Explore 101 assets in Metastatic Malignant Neoplasm In The Brain →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Stanford University
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06712927CT.gov Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | — | Recruiting | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT05704933CT.gov Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | — | Completed | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05048212CT.gov A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | — | Recruiting | — | — | — |
NCT05012254CT.gov Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT04511013CT.gov A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | — | Recruiting | — | — | — |
NCT04434560CT.gov Neoadjuvant Immunotherapy in Brain Metastases | — | Terminated | — | — | — |
NCT03873818CT.gov Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | — | Completed | — | — | — |
NCT03728465CT.gov Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | — | Terminated | — | — | — |
Show 7 more trialsShow fewer
NCT03297463CT.gov Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma | — | Withdrawn | — | — | — |
NCT02696993CT.gov Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02374242CT.gov Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT02115139CT.gov GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases | — | Completed | — | — | — |
NCT02097732CT.gov Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | — | Terminated | — | — | — |
NCT02460068CT.gov A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis | — | Unknown | — | — | — |
NCT02662725CT.gov Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm In The Brain
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | Stanford University | P3 | B · 62 |
| Trastuzumab | Iambic Therapeutics, Inc | P4 | BB |
| Trastuzumab Deruxtecan | Baptist Health South Florida | P4 | BB |
| Icotinib | Betta Pharmaceuticals Co., Ltd. | P3 | BB |
| Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Copper Cu 64-Dota-Trastuzumab | City of Hope Medical Center | P4 | BB |
| Regorafenib | Neonc Technologies, Inc. | P2 | BB |
| Memantine | NRG Oncology | P3 | BB |
| Zorifertinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P2/3 | B |
+42 more in the Metastatic Malignant Neoplasm In The Brain cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Metastatic Malignant Neoplasm In The Brain. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-metastatic-malignant-neoplasm-in-the-brain
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →